Incidence of IGH/TCR rearrangements and immunophenotype as a function of genotype
| . | MLL-AF4 (%) . | TEL-AML1 (%) . | BCR-ABL (%) . | E2A-PBX1 (%) . | FT-negative < 2 yrs (%) . | FT-negative 2-15 yrs (%) . | FT-negative* > 15 yrs (%) . | Total . |
|---|---|---|---|---|---|---|---|---|
| IGH | 11/14 (79) | 16/18 (89) | 25/25 (100) | 13/13 (100) | 5/6 (83) | 28/31 (90) | 26/33 (79) | 124/140 (89) |
| TCRG | 7/14 (50) | 15/18 (83) | 22/25† (88) | 0/13 (0) | 0/6 (00) | 20/31 (65) | 19/33 (58) | 83/140 (59) |
| Vδ2-Dδ3 | 5/13 (38) | 6/16 (38) | 5/23‡ (22) | 2/13 (15) | 3/4 (75) | — | — | — |
| CD34 | 8/13 (62) | 14/18 (78) | 23/25 (92) | 1/13 (8) | 4/5 (80) | — | — | — |
| CD10 | 0/14 (0) | 18/18 (100) | 25/25 (100) | 13/13 (100) | 5/6 (83) | — | — | — |
| CD22 | 7/14 (50) | 13/15 (87) | 18/21 (86) | 12/12 (100) | 5/5 (100) | — | — | — |
| CD20 | 0/14 (0) | 6/18 (33) | 11/24 (46) | 4/13 (31) | 4/6 (67) | — | — | — |
| cIgμ | 0/6 (0) | 1/11 (9) | 5/20 (25) | 10/12 (83) | 0/5 (0) | — | — | — |
| CD13 | 0/13 (0) | 7/18 (39) | 8/24 (33) | 1/12 (8) | 0/5 (0) | — | — | — |
| CD33 | 3/13 (23) | 5/16 (31) | 8/24 (33) | 1/13 (8) | 0/6 (0) | — | — | — |
| . | MLL-AF4 (%) . | TEL-AML1 (%) . | BCR-ABL (%) . | E2A-PBX1 (%) . | FT-negative < 2 yrs (%) . | FT-negative 2-15 yrs (%) . | FT-negative* > 15 yrs (%) . | Total . |
|---|---|---|---|---|---|---|---|---|
| IGH | 11/14 (79) | 16/18 (89) | 25/25 (100) | 13/13 (100) | 5/6 (83) | 28/31 (90) | 26/33 (79) | 124/140 (89) |
| TCRG | 7/14 (50) | 15/18 (83) | 22/25† (88) | 0/13 (0) | 0/6 (00) | 20/31 (65) | 19/33 (58) | 83/140 (59) |
| Vδ2-Dδ3 | 5/13 (38) | 6/16 (38) | 5/23‡ (22) | 2/13 (15) | 3/4 (75) | — | — | — |
| CD34 | 8/13 (62) | 14/18 (78) | 23/25 (92) | 1/13 (8) | 4/5 (80) | — | — | — |
| CD10 | 0/14 (0) | 18/18 (100) | 25/25 (100) | 13/13 (100) | 5/6 (83) | — | — | — |
| CD22 | 7/14 (50) | 13/15 (87) | 18/21 (86) | 12/12 (100) | 5/5 (100) | — | — | — |
| CD20 | 0/14 (0) | 6/18 (33) | 11/24 (46) | 4/13 (31) | 4/6 (67) | — | — | — |
| cIgμ | 0/6 (0) | 1/11 (9) | 5/20 (25) | 10/12 (83) | 0/5 (0) | — | — | — |
| CD13 | 0/13 (0) | 7/18 (39) | 8/24 (33) | 1/12 (8) | 0/5 (0) | — | — | — |
| CD33 | 3/13 (23) | 5/16 (31) | 8/24 (33) | 1/13 (8) | 0/6 (0) | — | — | — |
FT indicates fusion transcript.
Includes 2 cases > 55 years, neither of which demonstrated TCRG rearrangement. All cases expressed CD19. Only surface expression is considered positive, except for cIgμ. FT-positive cases are represented with their genotypic group.
18/20 (90%) in e1-a2 cases.
5/18 (28%) in e1-a2 cases.